Irvine-based Aviir, a venture-backed biotech firm targeting cardiac disease assessment, said late Monday that it has reached an agreement to raise up to $30M in a financing round. The firm said the round includes an initial $10M, plus up to $20M on meeting certain milestones. The funding was led by Merck Global Health Innovation Fund, and also included prior investors Bay City Capital, Aberdare Ventures, and New Leaf Venture Partners. Aviir said the funding will go towards commercialization of its cardiac risk assessment technology. More information »